Loading
A phase 1/2 trial of AVM0703 in advanced solid tumours, run by AVM Biotechnology Inc, now recruiting.
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies is a phase 1/2 interventional study registered as NCT04329728 by AVM Biotechnology Inc, with 144 participants planned, started 2020-11-06 and due to reach its primary completion in 2027-11-30. Interventions recorded: AVM0703.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/